Hence, to investigate the role of CCL26 in OSCC on tumor immunity, we next analyzed the ratio and absolute number of key immunocytes in peripheral blood of OSCC patients (n = 28) by flow cytometry (CCL26high and CCL26low groups):CD3+ T cells, CD3+CD4+ helper/inducer T cells, CD3+CD8+ cytotoxic T cells, CD3−CD19+ B cells, and CD3−CD16+, and/or CD56+ NK cells (Figure 6A). The gene discussed is CCL26; the disease is neoplasm.